[rhIL-11 accelerates the engraftment of platelets after unrelated cord blood transplantation].
OBJECTIVE
To observe whether rhIL-11 could accelerate the engraftment of platelets after unrelated cord blood transplantation (CBT).


METHODS
Nine patients (3 children and 6 adults) were enrolled in this study. The degree of HLA disparity was 0-2 loci. Cord blood was given two units for adults and one unit for children. Conditioning regimens were CY/TBI in 1 and BU/CY in 8 cases, both with antithymocyte globulin. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and short-term methotrexate. On day +1, rhIL-11 was used at 50 microg x kg(-1) x d(-1) and G-CSF at 5 microg x kg(-1) x d(-1) to accelerate hematopoiesis recovery.


RESULTS
The median age of the patients was 22.3 years and the median weight 52.3 kg. Among the 9 patients, 8 (88.9%) experienced engraftment. The median time to neutrophil > 0.5 x 10(9)/L was 21.3 (14-37) days and to platelet > 20 x 10(9)/L was 25 (18-36) days. 42.9% of the patients developed grade I aGVHD and 33.3% developed localized chronic GVHD. Six patients were alive and disease-free at a median follow-up of 7 months. Infection was the primary cause of death. The expected 1-year survival was 77.8%, 2-year survival was 52.2%. Five of 8 patients (62.5%) who received IL-11 presented leakage syndrome. On prophylaxis with drugs containing Arnebia root extract, all patients could tolerate the treatment.


CONCLUSIONS
rhIL-11 maybe helpful for accelerating the platelet recovery and reducing aGVHD severity in unrelated CBT. The major side effect is leakage syndrome. It is well tolerated on prophylaxis with drugs containing Arnebia root.
Wang
Mang-ju
MJ
Department of Hematology, Peking University First Hospital, Beijing, China.
Ren
Han-yun
HY
Cen
Xi-nan
XN
Qiu
Zhi-xiang
ZX
Xu
Wei-lin
WL
Ou
Jin-ping
JP
Li
Yuan
Y
Wang
Wen-sheng
WS
Wang
Li-hong
LH
Shi
Yong-jin
YJ
Zhu
Qiang
Q
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D002648:Child; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D017370:Interleukin-11 / Q000494:pharmacology*; D008297:Male; D011994:Recombinant Proteins / Q000494:pharmacology
D017370:Interleukin-11; D011994:Recombinant Proteins